Brokerages Set Alector, Inc. (NASDAQ:ALEC) Price Target at $4.17

Shares of Alector, Inc. (NASDAQ:ALEC) have been given an average recommendation of “Hold” by the seven research firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $4.1667.

A number of analysts have recently weighed in on ALEC shares. Mizuho upgraded shares of Alector from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $2.50 to $3.50 in a research note on Monday, July 28th. Wall Street Zen raised Alector from a “sell” rating to a “hold” rating in a report on Saturday, September 13th.

Alector Stock Performance

Shares of ALEC opened at $3.16 on Monday. The stock has a 50-day moving average of $2.28 and a two-hundred day moving average of $1.64. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.78 and a current ratio of 3.78. The stock has a market cap of $319.82 million, a P/E ratio of -2.72 and a beta of 0.99. Alector has a one year low of $0.87 and a one year high of $6.14.

Alector (NASDAQ:ALEC) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. Alector had a negative return on equity of 112.06% and a negative net margin of 142.10%.The firm had revenue of $7.87 million during the quarter, compared to analysts’ expectations of $2.76 million. Alector has set its FY 2025 guidance at EPS. As a group, research analysts predict that Alector will post -1.88 EPS for the current year.

Insider Activity

In related news, Director Paula Hammond sold 14,000 shares of the stock in a transaction on Tuesday, August 26th. The shares were sold at an average price of $2.36, for a total transaction of $33,040.00. Following the sale, the director directly owned 74,909 shares of the company’s stock, valued at approximately $176,785.24. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 9.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Squarepoint Ops LLC acquired a new stake in shares of Alector during the 4th quarter valued at about $25,000. FNY Investment Advisers LLC lifted its position in shares of Alector by 100.0% during the 2nd quarter. FNY Investment Advisers LLC now owns 20,000 shares of the company’s stock valued at $28,000 after buying an additional 10,000 shares in the last quarter. Prudential Financial Inc. acquired a new stake in Alector in the 2nd quarter valued at $30,000. CWM LLC increased its holdings in Alector by 370.7% in the 1st quarter. CWM LLC now owns 33,643 shares of the company’s stock worth $41,000 after acquiring an additional 26,495 shares in the last quarter. Finally, Cerity Partners LLC purchased a new stake in Alector in the 1st quarter worth $51,000. Institutional investors and hedge funds own 85.83% of the company’s stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.